HK1046863B - 治療糖尿病的fbp酶抑制劑與胰島素致敏劑的組合 - Google Patents

治療糖尿病的fbp酶抑制劑與胰島素致敏劑的組合

Info

Publication number
HK1046863B
HK1046863B HK02108475.5A HK02108475A HK1046863B HK 1046863 B HK1046863 B HK 1046863B HK 02108475 A HK02108475 A HK 02108475A HK 1046863 B HK1046863 B HK 1046863B
Authority
HK
Hong Kong
Prior art keywords
diabetes
treatment
combination
insulin
insulin sensitizers
Prior art date
Application number
HK02108475.5A
Other languages
English (en)
Other versions
HK1046863A1 (en
Inventor
D Erion Mark
Vanpoelje Paul
Original Assignee
症變治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 症變治療公司 filed Critical 症變治療公司
Publication of HK1046863A1 publication Critical patent/HK1046863A1/xx
Publication of HK1046863B publication Critical patent/HK1046863B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HK02108475.5A 1998-12-24 2002-11-22 治療糖尿病的fbp酶抑制劑與胰島素致敏劑的組合 HK1046863B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
PCT/US1999/030713 WO2000038666A2 (en) 1998-12-24 1999-12-22 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
HK1046863A1 HK1046863A1 (en) 2003-01-30
HK1046863B true HK1046863B (zh) 2008-07-25

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108475.5A HK1046863B (zh) 1998-12-24 2002-11-22 治療糖尿病的fbp酶抑制劑與胰島素致敏劑的組合

Country Status (25)

Country Link
EP (1) EP1143955B1 (zh)
JP (1) JP2003515523A (zh)
KR (3) KR100689943B1 (zh)
CN (3) CN1714866A (zh)
AT (1) ATE300288T1 (zh)
AU (1) AU771039B2 (zh)
BR (1) BR9917005A (zh)
CA (1) CA2354053A1 (zh)
CZ (1) CZ20012353A3 (zh)
DE (1) DE69926400T2 (zh)
DK (1) DK1143955T3 (zh)
ES (1) ES2246586T3 (zh)
HK (1) HK1046863B (zh)
HU (1) HUP0402506A3 (zh)
ID (1) ID30237A (zh)
IL (2) IL143569A0 (zh)
MX (1) MXPA01006511A (zh)
NO (1) NO20013115L (zh)
NZ (1) NZ512219A (zh)
PL (1) PL352756A1 (zh)
PT (1) PT1143955E (zh)
RU (2) RU2227749C2 (zh)
SK (1) SK9172001A3 (zh)
WO (1) WO2000038666A2 (zh)
ZA (1) ZA200105016B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU761267C (en) 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
SK8892002A3 (en) 1999-12-22 2003-04-01 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
ATE350385T1 (de) 2000-03-08 2007-01-15 Metabasis Therapeutics Inc Neue aryl fructose-1,6-bisphosphatase inhibitoren
CN101301294A (zh) * 2000-07-06 2008-11-12 症变治疗公司 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
EP1504014B1 (en) 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
EP1532157A4 (en) 2002-05-13 2009-02-25 Metabasis Therapeutics Inc NEW PRODRUGS FROM PMEA TO PHOSPHONIC ACID BASE AND ITS ANALOG
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
BRPI0407403B1 (pt) * 2003-02-11 2022-07-19 Cancer Research Technology Ltd Compostos de isoxazol e composição farmacêutica
PT1700856E (pt) * 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
US20070225259A1 (en) * 2004-08-18 2007-09-27 Qun Dang Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
EP1857118A1 (en) * 2004-12-13 2007-11-21 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
TW200633702A (en) * 2004-12-15 2006-10-01 Sankyo Co Medicinal composition containing fbpase inhibitor
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6110903A (en) * 1997-03-07 2000-08-29 Sankyo Company Ltd. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
DE69926400T2 (de) 2006-05-24
BR9917005A (pt) 2002-04-02
NO20013115L (no) 2001-08-24
HUP0402506A3 (en) 2007-05-29
NO20013115D0 (no) 2001-06-21
EP1143955A3 (en) 2002-08-28
HUP0402506A2 (hu) 2005-04-28
KR20070046210A (ko) 2007-05-02
HK1046863A1 (en) 2003-01-30
CN101164618A (zh) 2008-04-23
JP2003515523A (ja) 2003-05-07
NZ512219A (en) 2004-12-24
ES2246586T3 (es) 2006-02-16
CN100352505C (zh) 2007-12-05
AU2058300A (en) 2000-07-31
CN1714866A (zh) 2006-01-04
ATE300288T1 (de) 2005-08-15
CN1350466A (zh) 2002-05-22
MXPA01006511A (es) 2004-03-19
KR100689943B1 (ko) 2007-03-08
EP1143955B1 (en) 2005-07-27
WO2000038666A2 (en) 2000-07-06
PT1143955E (pt) 2005-11-30
DK1143955T3 (da) 2005-11-14
SK9172001A3 (en) 2002-04-04
EP1143955A2 (en) 2001-10-17
KR20060114724A (ko) 2006-11-07
CZ20012353A3 (cs) 2001-12-12
DE69926400D1 (de) 2005-09-01
ZA200105016B (en) 2002-09-19
ID30237A (id) 2001-11-15
RU2227749C2 (ru) 2004-04-27
IL143569A (en) 2006-06-11
PL352756A1 (en) 2003-09-08
RU2003132054A (ru) 2005-04-20
CA2354053A1 (en) 2000-07-06
KR20010099942A (ko) 2001-11-09
IL143569A0 (en) 2002-04-21
WO2000038666A3 (en) 2001-11-29
AU771039B2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
HK1059213A1 (en) Treatment of type 2 diabetes with inhibitors of dipetidyl peptidase iv
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
UA85041C2 (ru) Способ лечения кишечной непроходимости
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
SI1427409T1 (sl) Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
AU7564396A (en) Rac-proteine kinase as therapeutic agent or in diagnostics
TNSN07372A1 (en) Method of treating or preventing type - 2 diabetes
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
WO2003103597A3 (en) DIAGNOSIS AND TREATMENT OF DIABETES AND INSULIN RESISTANCE
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
WO2003103601A3 (en) DIAGNOSIS AND TREATMENT METHODS FOR DIABETES AND INSULIN RESISTANCE
AU5434899A (en) Cancer treatment
AU5890499A (en) Use of composition in the treatment of schizophrenia
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу
UA30659A (uk) Спосіб купіровання опіатної залежності
UA32255A (uk) Спосіб лікування цукрового діабету

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111222